Loading
Health In Tech, Inc. Stock: price and insider trades · United States
Health In Tech, Inc.: what insiders have been doing
Health In Tech, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Health In Tech, Inc. logged 32 filings by 10 insiders.
No insider bought on the market over the period, while 2 insiders filed 4 sales totalling €32k. At €9,399, the sale published on 11 September 2026 by Hayes Timothy is the largest of the period (0.019% of market cap).
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 32 filings here. Since 2025, the database holds no purchases and 4 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
47
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€32,463
4 ops. · all time
Who traded when
BuySaleTimothy Hayes3 sales
Zain Syed Hasan1 sale
Analyst consensus: bullish or bearish?
Analysts rate Health In Tech, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$3.12.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,965 of 24,148 companies
49.5
score / 100
Value41
Quality58
FCF yld-0.1%
Earn yld3.1%
EV/EBITDA16.0x
ROE-22%
Gross mgn63%
Net mgn3.8%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.63
Analyst consensus
3 analystsStrong buy
US$1.25Target US$3.12(+396%)US$4.10
Income statement
RevenueUS$33.3M
Gross profitUS$20.9M63% margin
EBITDAUS$2.6M8% margin
Net incomeUS$1.3M-12.0% margin
Valuation
PER (forward)-31.4x
P/Book2.1x
Balance sheet & cash
Market capUS$41.1M
Total debtUS$139.8k
Free Cash Flow-US$56.1k
Debt / Equity1%
Profitability & ownership
ROE-21.9%
ROA-12.7%
% insiders67.7%
% institutions8.8%
Last declaration on 9 October 2026
Declarations47 total
26,301 shares@ US$0.760.040% mcap10.7% of flowClass A Common StockSEC:0001213900-26-108502:0
26,301 shares@ US$0.760.040% mcap14.8% of flowClass A Common StockSEC:0001213900-26-108500:0
4,795 shares@ US$0.890.0075% mcap15.0% of flowClass A Common StockSEC:0001213900-26-100594:0
63,339 shares@ US$0.890.100% mcap27.3% of flowClass A Common StockSEC:0001213900-26-100590:0
33,725 shares@ US$0.890.053% mcap24.7% of flowClass A Common StockSEC:0001213900-26-100592:0
12,000 shares@ US$0.8930.019% mcap6.2% of flowClass A Common StockSEC:0001213900-26-100128:0
17,730 shares@ US$0.92290.029% mcap9.5% of flowCommonSEC144:0001654954-26-008337
12,000 shares@ US$0.8980.019% mcap6.3% of flowCommonSEC144:0001654954-26-008344
11,667 shares@ US$0.920.019% mcap37.4% of flowClass A Common StockSEC:0001213900-26-099471:0
5,730 shares@ US$0.930.0093% mcap3.1% of flowClass A Common StockSEC:0001213900-26-099421:0
12,000 shares@ US$0.910.019% mcap6.3% of flowClass A Common StockSEC:0001213900-26-099421:1
18,334 shares@ US$0.93650.027% mcap55.7% of flowCommonSEC144:0001654954-26-008258
4,007 shares@ US$1.060.0075% mcap14.9% of flowClass A Common StockSEC:0001213900-26-090790:0
46,327 shares@ US$1.060.087% mcap23.8% of flowClass A Common StockSEC:0001213900-26-090793:0
28,183 shares@ US$1.060.053% mcap24.6% of flowClass A Common StockSEC:0001213900-26-090796:0
28,725 shares@ US$1.040.053% mcap24.8% of flowClass A Common StockSEC:0001213900-26-079323:0
4,084 shares@ US$1.040.0076% mcap15.0% of flowClass A Common StockSEC:0001213900-26-079326:0
47,217 shares@ US$1.040.087% mcap24.0% of flowClass A Common StockSEC:0001213900-26-079324:0
18,867 shares@ US$1.060.036% mcap17.2% of flowClass A Common StockSEC:0001213900-26-077302:0
18,867 shares@ US$1.060.036% mcap17.2% of flowClass A Common StockSEC:0001213900-26-077303:0
18,867 shares@ US$1.060.036% mcap11.8% of flowClass A Common StockSEC:0001213900-26-077301:0
35,140 shares@ US$1.500.080% mcap24.9% of flowClass A Common StockSEC:0001213900-26-045210:0
3,448 shares@ US$1.500.0078% mcap17.7% of flowClass A Common StockSEC:0001213900-26-045214:0
21,480 shares@ US$1.500.049% mcap25.9% of flowClass A Common StockSEC:0001213900-26-045212:0
5,000 shares0Class A Common StockSEC:0001213900-26-043124:0
25 of 47 declarations
About Health In Tech, Inc.
Health In Tech, Inc. (ticker: HIT) is a U.S.-listed insurtech company traded on the American NYSE/NASDAQ market, and incorporated in the United States in the State of Nevada. The company is headquartered in Stuart, Florida, and positions itself at the intersection of health insurance and technology, with a business model focused on simplifying, automating, and accelerating the sales and servicing workflows for self-funded health plans and related insurance solutions. According to its SEC filings, HIT was incorporated in November 2021 and was formed to consolidate several standalone businesses into a single operating structure, including Stone Mountain Risk (SMR), Health Intelligence Card (Hi Card), and International Captive Exchange (ICE). ([sec.gov](https://www.sec.gov/Archives/edgar/data/0002019505/000121390026034211/ea0283147-10k_health.htm?utm_source=openai))
Operationally, Health In Tech describes itself as an AI-enabled insurance technology platform and marketplace aimed at improving healthcare-industry processes through vertical integration, process simplification, and automation. Its proprietary eDIYBS platform is marketed to streamline quoting and binding for self-funded health plans for larger employers and level-funded plans for small and mid-sized businesses. HIT primarily serves brokers, third-party administrators (TPAs), carriers, and managing general underwriters (MGUs), which places it closer to a technology-enabled distribution and workflow platform than a traditional carrier. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2019505/000121390026047605/ea0287599-s3_health.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, the company’s value proposition centers on reducing sales-cycle friction in a complex, fragmented, and administratively intensive U.S. health-benefits market. HIT states that it operates across all 50 U.S. states, giving it national reach even though its corporate base and management functions are concentrated in Florida. Its core offerings include self-funded health-plan enablement, quote-and-bind workflows, stop-loss solutions through Stone Mountain Risk, and ancillary product lines that broaden the platform’s scope, including critical illness, accident, dental, vision, term life, and GAP coverage. ([healthintech.com](https://healthintech.com/about/?utm_source=openai))
Recent developments suggest an active growth and capital-markets agenda. In SEC filings and company communications, HIT has highlighted commercial expansion, additional ancillary products, and brand-building initiatives such as its 2026 hitDavos event. The company also disclosed a PIPE financing in March 2026 and has been the subject of Form 4 insider-transaction filings, underscoring continued shareholder activity and market attention. For investors, HIT should be viewed as a U.S. small-cap insurtech with an offensive growth profile, exposed to the expansion of self-funded healthcare plans, but also to execution risk, commercial dependence, and potential dilution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2019505/000121390026034716/ea0283456-8k_health.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
